1 of 1
Story summary
- Enveda secured $311 million Series E funding at a $2 billion valuation.
- Catalio Capital Management led the round, with Iconiq and other investors participating.
- The new valuation doubles Enveda’s worth compared with twelve months earlier.
- Enveda uses AI to discover medicines from plants and microbes rather than synthetic labs.
- Enveda is testing a severe-skin-condition drug and a weight-loss maintenance candidate in patients.
